Molecular structure of Anacetrapib, CAS Number: 875446-37-0
Anacetrapib (CAS 875446-37-0)
Application:
Anacetrapib is a potent and selective CETP inhibitor
CAS Number:
875446-37-0
Purity:
≥99%
Molecular Weight:
637.51
Molecular Formula:
C30H25F10NO3
Supplemental Information:
This product is subject to an additional Dangerous Goods shipping charge.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Anacetrapib is a potent and selective CETP inhibitor for rhCETP and C13S CETP mutants with IC50 of 7.9 nM and 11.8 nM, respectively.
Anacetrapib (CAS 875446-37-0) References
- Anacetrapib: hope for CETP inhibitors? | Gurfinkel, R. and Joy, TR. 2011. Cardiovasc Ther. 29: 327-39. PMID: 20406242
- Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport. | Niesor, EJ., et al. 2010. J Lipid Res. 51: 3443-54. PMID: 20861162
- Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors. | Miyares, MA. 2011. Ann Pharmacother. 45: 84-94. PMID: 21205945
- Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction. | Gutstein, DE., et al. 2012. Clin Pharmacol Ther. 91: 109-22. PMID: 22130116
- Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors? | Page, MM., et al. 2016. Expert Opin Pharmacother. 17: 275-81. PMID: 26642232
- Pharmacokinetic drug evaluation of anacetrapib for the treatment of dyslipidemia. | Borghi, C. and Cicero, AF. 2017. Expert Opin Drug Metab Toxicol. 13: 205-209. PMID: 27852117
- Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias? | Filippatos, TD., et al. 2017. Diseases. 5: PMID: 28961179
- The effect and safety of anacetrapib in the treatment of dyslipidemia: a systematic review and meta-analysis. | Zhou, J., et al. 2018. Postgrad Med. 130: 129-136. PMID: 29135318
- Anacetrapib as a potential cardioprotective strategy. | Di Bartolo, BA. and Nicholls, SJ. 2017. Drug Des Devel Ther. 11: 3497-3502. PMID: 29263647
- Is Anacetrapib Better Than Its CETP Inhibitor Counterparts? | Grabie, M., et al. 2019. Cardiol Rev. 27: 242-248. PMID: 30601160
Inhibitor of:
apoA-I, apoA-II, apoE, CETP, Hepatic Lipase, LCAT, and REP-2.Activator of:
apoA-V, and CETP.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Anacetrapib, 10 mg | sc-364404 | 10 mg | $615.00 | |||
Anacetrapib, 50 mg | sc-364404A | 50 mg | $1785.00 |